FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555266496> ?p ?o ?g. }

• W2555266496 endingPage "942" @default.
• W2555266496 startingPage "942" @default.
• W2555266496 abstract "Abstract CPX-351, a liposomal formulation of cytarabine:daunorubicin co-encapsulated at a synergistic 5:1 molar drug ratio, has been previously shown to be highly active in various preclinical leukemia models. In the present investigations, we utilized a bone marrow engrafted human lymphocytic leukemia xenograft model in order to elucidate the pharmacodynamic basis for its superior efficacy compared to un-encapsulated cytarabine:daunorubicin combinations. In normal bone marrow, the un-encapsulated cytarabine:daunorubicin saline-based cocktail and CPX-351 provided comparable cell suppression after intravenous treatment at maximum tolerated dose. In contrast, when these formulations were administered to tumor bearing mice, CPX-351 completely ablated leukemia cells from the bone marrow for multiple weeks whereas the saline-based drug cocktail induced only transient leukemia suppression. Examination of drug levels in the bone marrow compartment revealed that cytarabine:daunorubicin concentrations were significantly elevated for CPX-351. More striking was the observation that whereas bone marrow drug concentrations over time appeared comparable after each dose of the saline-based drug cocktail, the first dose of CPX-351 promoted elevated bone marrow drug accumulation for subsequent doses. Under these conditions, the cytarabine:daunorubicin ratio in bone marrow was maintained near the administered 5:1 molar ratio for CPX- 351 while the drug ratio changed more than 100-fold within 4 hours after administration of the saline-based drug cocktail. Confocal fluorescence microscopy of leukemia cells exposed to CPX-351 in vitro revealed that CPX-351 liposomes were taken up into cytoplasmic vacuoles and subsequently released their drug contents intracellularly. Taken together, these results indicate that the improved efficacy observed following CPX-351 administration in vivo is related to liposome-mediated prolonged and direct exposure of leukemia cells to synergistic drug ratios." @default.
• W2555266496 created "2016-11-30" @default.
• W2555266496 creator A5014471137 @default.
• W2555266496 creator A5014898667 @default.
• W2555266496 creator A5016866908 @default.
• W2555266496 creator A5020081255 @default.
• W2555266496 creator A5041093263 @default.
• W2555266496 creator A5063148116 @default.
• W2555266496 creator A5067801513 @default.
• W2555266496 creator A5068680030 @default.
• W2555266496 creator A5071405218 @default.
• W2555266496 creator A5075335611 @default.
• W2555266496 creator A5089111450 @default.
• W2555266496 date "2008-11-16" @default.
• W2555266496 modified "2023-09-26" @default.
• W2555266496 title "Synergistic Cytarabine:Daunorubicin Ratios Delivered by CPX-351 to Human Leukemia Xenografts Is Associated with Liposome-Mediated Bone Marrow Drug Accumulation, Intracellular Delivery of Encapsulated Agents to Leukemia Cells, and Increased Efficacy." @default.
• W2555266496 doi "https://doi.org/10.1182/blood.v112.11.942.942" @default.
• W2555266496 hasPublicationYear "2008" @default.
• W2555266496 type Work @default.
• W2555266496 sameAs 2555266496 @default.
• W2555266496 citedByCount "2" @default.
• W2555266496 crossrefType "journal-article" @default.
• W2555266496 hasAuthorship W2555266496A5014471137 @default.
• W2555266496 hasAuthorship W2555266496A5014898667 @default.
• W2555266496 hasAuthorship W2555266496A5016866908 @default.
• W2555266496 hasAuthorship W2555266496A5020081255 @default.
• W2555266496 hasAuthorship W2555266496A5041093263 @default.
• W2555266496 hasAuthorship W2555266496A5063148116 @default.
• W2555266496 hasAuthorship W2555266496A5067801513 @default.
• W2555266496 hasAuthorship W2555266496A5068680030 @default.
• W2555266496 hasAuthorship W2555266496A5071405218 @default.
• W2555266496 hasAuthorship W2555266496A5075335611 @default.
• W2555266496 hasAuthorship W2555266496A5089111450 @default.
• W2555266496 hasConcept C203014093 @default.
• W2555266496 hasConcept C2778041864 @default.
• W2555266496 hasConcept C2778461978 @default.
• W2555266496 hasConcept C2780007613 @default.
• W2555266496 hasConcept C2781021840 @default.
• W2555266496 hasConcept C71924100 @default.
• W2555266496 hasConcept C98274493 @default.
• W2555266496 hasConceptScore W2555266496C203014093 @default.
• W2555266496 hasConceptScore W2555266496C2778041864 @default.
• W2555266496 hasConceptScore W2555266496C2778461978 @default.
• W2555266496 hasConceptScore W2555266496C2780007613 @default.
• W2555266496 hasConceptScore W2555266496C2781021840 @default.
• W2555266496 hasConceptScore W2555266496C71924100 @default.
• W2555266496 hasConceptScore W2555266496C98274493 @default.
• W2555266496 hasIssue "11" @default.
• W2555266496 hasLocation W25552664961 @default.
• W2555266496 hasOpenAccess W2555266496 @default.
• W2555266496 hasPrimaryLocation W25552664961 @default.
• W2555266496 hasRelatedWork W2053430911 @default.
• W2555266496 hasRelatedWork W2058863425 @default.
• W2555266496 hasRelatedWork W2082440968 @default.
• W2555266496 hasRelatedWork W2113871094 @default.
• W2555266496 hasRelatedWork W2136112505 @default.
• W2555266496 hasRelatedWork W2424199172 @default.
• W2555266496 hasRelatedWork W2483620080 @default.
• W2555266496 hasRelatedWork W2555266496 @default.
• W2555266496 hasRelatedWork W2768155247 @default.
• W2555266496 hasRelatedWork W4283806841 @default.
• W2555266496 hasVolume "112" @default.
• W2555266496 isParatext "false" @default.
• W2555266496 isRetracted "false" @default.
• W2555266496 magId "2555266496" @default.
• W2555266496 workType "article" @default.